AZD1152 in Patients With Advanced Solid Malignancies-Study 3
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.
Solid Tumours
DRUG: AZD1152
Safety and Tolerability, Assessed at each visit
Pharmacokinetics, Assessed at predetermined timepoints after dose administration|Effect on biomarkers, Assessed after treatment|Anti-tumor activity, Assessed at the end of treatment
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.